See more : Fortum Oyj (FOJCF) Income Statement Analysis – Financial Results
Complete financial analysis of Scopus BioPharma Inc. (SCPS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Scopus BioPharma Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Meitav DASH Investments Ltd (MTDS.TA) Income Statement Analysis – Financial Results
- Accsys Technologies PLC (AXS.AS) Income Statement Analysis – Financial Results
- Financial Street Holdings Co., Ltd. (000402.SZ) Income Statement Analysis – Financial Results
- NAOS Emerging Opportunities Company Limited (NCC.AX) Income Statement Analysis – Financial Results
- 888 Holdings plc (888.L) Income Statement Analysis – Financial Results
Scopus BioPharma Inc. (SCPS)
About Scopus BioPharma Inc.
Scopus BioPharma Inc., a clinical-stage biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases. The company lead development programs are immuno-oncology gene therapy for the treatment of various cancers. It offers Duet Platform, a CpG signal transducer and activator of transcription 3 (STAT3) inhibitors; and MRI-1867, rationally designed, orally available, dual-action, hybrid, and small molecule that is an inverse agonist of the endocannabinoid system/cannabinoid receptor 1, as well as an inhibitor of inducible nitric oxide synthase. Scopus BioPharma Inc. has strategic partnerships with the City of Hope, National Institutes of Health Program, and The Hebrew University of Jerusalem for its lead development and other programs. The company was formerly known as Project18 Inc. and changed its name to Scopus BioPharma Inc. in December 2017. Scopus BioPharma Inc. was incorporated in 2017 and is headquartered in New York, New York.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 2.68M | 15.02M | 7.42M | 463.11K | 277.54K |
| General & Administrative | 9.03M | 12.61M | 2.73M | 2.23M | 408.43K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 9.03M | 12.61M | 2.73M | 2.23M | 408.43K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 11.71M | 27.63M | 10.16M | 2.69M | 685.96K |
| Cost & Expenses | 11.71M | 27.63M | 10.16M | 2.69M | 685.96K |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 774.68K | 706.45K | 0.00 | 0.00 |
| Depreciation & Amortization | 1.73K | 1.50K | 1.44K | 664.00 | 161.14K |
| EBITDA | -11.71M | -27.63M | -10.15M | -2.69M | -685.96K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -11.71M | -27.63M | -10.16M | -2.69M | -685.96K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 0.00 | 681.21K | -706.45K | 0.00 | 0.00 |
| Income Before Tax | -11.71M | -26.95M | -10.86M | -2.69M | -685.96K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -105.05K | 774.68K | 706.45K | 1.00 | -847.11K |
| Net Income | -11.61M | -27.73M | -11.57M | -2.69M | -685.96K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.55 | -1.61 | -0.87 | -0.18 | -0.05 |
| EPS Diluted | -0.55 | -1.61 | -0.87 | -0.18 | -0.05 |
| Weighted Avg Shares Out | 21.09M | 17.25M | 13.36M | 14.98M | 14.98M |
| Weighted Avg Shares Out (Dil) | 21.09M | 17.25M | 13.36M | 14.98M | 14.98M |
Scopus BioPharma's Subsidiary — Duet BioTherapeutics — Presents Compelling New Data for a Novel Treatment for Malignant Glioma at 38th Annual Meeting of the Society for Immunotherapy of Cancer
Scopus BioPharma's Subsidiary — Duet BioTherapeutics — to Present at the 38th Annual Meeting of the Society for Immunotherapy of Cancer
Scopus BioPharma's Subsidiary — Duet BioTherapeutics — to Present at the 3rd Annual STING & TLR-Targeting Therapies Summit
Scopus BioPharma Announces Adjournment of Annual Meeting of Stockholders
Scopus BioPharma to Present at the LD Micro Main Event
Scopus BioPharma Retaining Counsel to Investigate Unusual Market Activity
Scopus BioPharma to Present at MicroCap Rodeo's Fall Harvest Best Ideas Conference
Scopus BioPharma's Subsidiary — Duet Therapeutics — Announces Release of Preclinical Data Being Presented at 17th Annual Meeting of the Oligonucleotide Therapeutics Society
Scopus BioPharma's Subsidiary Duet Therapeutics Set to Release Scientific Data During the 17th Annual Meeting of the Oligonucleotide Therapeutics Society
Scopus BioPharma's Subsidiary — Duet Therapeutics — Set to Release Scientific Data During the 17th Annual Meeting of the Oligonucleotide Therapeutics Society
Source: https://incomestatements.info
Category: Stock Reports